HPLC_UV Method for Quantification of Favipiravir in Pharmaceutical Formulations

Background: After the break, out of corona virus at 2019 it was named as SARS_COVID19 and researches on virus and its therapy started. The pandemic of corona caused many deaths all over the world as its novelty, hardened the treatment process. Available anti-viral medications used and tested for the treatment and at the same time, many researchers started to work on these medications. Mentioned drugs were tested for their effectiveness, with different methods of testing. Objective: HPLC_UV Method for Quantification of Favipiravir in Pharmaceutical Formulations.Method: One of the frequently used methods, HPLC, was used to quantify anti-viral drugs in their dosage form or in human or animal plasma. Favipiravir is one of the drugs of interest in those researches. Favipiravir, which is also known as T-705, is a newly invented drug compared to other antivirals. It is used in different cases of Ebola and influenza pandemics but not officially available in any pharmacopeia yet. After the pandemic of corona Favipiravir rose an attention to its therapeutically potentials against novel viruses. As it is not used widely, the resistance of viruses against Favipiravir is less. After many clinical trials, it was approved as a therapeutic choice for mild to moderate SARS_COVID19 patients whom are conscious and have the ability to swallow the tablet. Afterwards many researches for quantifying the drug with different analytical methods started. The purpose was to quantify the drug in its tablet dosage form or in human spiked plasma and even in animal blood samples. Results and Conclusion: The results of these researches could help the producer companies, research clinics and at the very critical point, the final goal could be saving lives of patients. Hereby in this thesis project, an overall information on Favipiravir and the HPLC_UV analytical researches on this drug are mentioned.